[go: up one dir, main page]

WO1996039195A3 - Oligonucleotide chimiquement modifie pour mutagenese dirigee sur site - Google Patents

Oligonucleotide chimiquement modifie pour mutagenese dirigee sur site Download PDF

Info

Publication number
WO1996039195A3
WO1996039195A3 PCT/US1996/008883 US9608883W WO9639195A3 WO 1996039195 A3 WO1996039195 A3 WO 1996039195A3 US 9608883 W US9608883 W US 9608883W WO 9639195 A3 WO9639195 A3 WO 9639195A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemically modified
site
directed mutagenesis
modified oligonucleotide
molecule
Prior art date
Application number
PCT/US1996/008883
Other languages
English (en)
Other versions
WO1996039195A2 (fr
Inventor
Peter M Glazer
Pamela A Havre
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Priority to AU60432/96A priority Critical patent/AU6043296A/en
Publication of WO1996039195A2 publication Critical patent/WO1996039195A2/fr
Publication of WO1996039195A3 publication Critical patent/WO1996039195A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un oligonucléotide mutagène formant un triplex et ses procédés d'utilisation. L'oligonucléotide est chimiquement modifié afin de contenir un mutagène incorporé et forme une molécule d'acide nucléique à trois brins avec un segment spécifique d'ADN d'une molécule cible d'ADN. Lorsque le triplex est formé, le mutagène est rapproché de la molécule cible et provoque une mutation sur un site spécifique de celle-ci. La mutation active, désactive ou modifie l'activité et la fonction de la molécule cible.
PCT/US1996/008883 1995-06-06 1996-06-04 Oligonucleotide chimiquement modifie pour mutagenese dirigee sur site WO1996039195A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60432/96A AU6043296A (en) 1995-06-06 1996-06-04 Chemically modified oligonucleotide for site-directed mutage nesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46351995A 1995-06-06 1995-06-06
US463,519 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039195A2 WO1996039195A2 (fr) 1996-12-12
WO1996039195A3 true WO1996039195A3 (fr) 1997-01-30

Family

ID=23840376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008883 WO1996039195A2 (fr) 1995-06-06 1996-06-04 Oligonucleotide chimiquement modifie pour mutagenese dirigee sur site

Country Status (2)

Country Link
AU (1) AU6043296A (fr)
WO (1) WO1996039195A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136601A (en) * 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10272019B2 (en) 2014-05-09 2019-04-30 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
WO2017143061A1 (fr) 2016-02-16 2017-08-24 Yale University Compositions et procédés pour le traitement de la mucoviscidose
WO2017143042A2 (fr) 2016-02-16 2017-08-24 Yale University Compositions permettant d'améliorer l'édition ciblée de gènes et leurs procédés d'utilisation
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
WO2020033951A1 (fr) 2018-08-10 2020-02-13 Yale University Compositions et procédés d'édition de gène embryonnaire in vitro
US20210338815A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
WO2020112195A1 (fr) 2018-11-30 2020-06-04 Yale University Compositions, technologies et procédés d'utilisation de plérixafor pour améliorer l'édition de gènes
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2020257776A1 (fr) 2019-06-21 2020-12-24 Yale University Compositions d'acides nucléiques peptidiques ayant des segments de liaison de type hoogsteen modifiés et leurs procédés d'utilisation
US20220339294A1 (en) 2019-09-09 2022-10-27 Yale University Nanoparticles for selective tissue or cellular uptake

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253193A2 (fr) * 1986-07-08 1988-01-20 Abbott Laboratories Méthode de mutagénèse par réparation dirigée à l'aide d'oligonucléotides d'une rupture de brin
US5354670A (en) * 1991-12-24 1994-10-11 The President And Fellows Of Harvard College Site-directed mutagenesis of DNA
WO1995001364A1 (fr) * 1993-06-25 1995-01-12 Yale University Oligonucleotide modifie chimiquement en vue d'une mutagenese dirigee vers le site

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253193A2 (fr) * 1986-07-08 1988-01-20 Abbott Laboratories Méthode de mutagénèse par réparation dirigée à l'aide d'oligonucléotides d'une rupture de brin
US5354670A (en) * 1991-12-24 1994-10-11 The President And Fellows Of Harvard College Site-directed mutagenesis of DNA
WO1995001364A1 (fr) * 1993-06-25 1995-01-12 Yale University Oligonucleotide modifie chimiquement en vue d'une mutagenese dirigee vers le site

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GASPARRO F P ET AL: "Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: Characterization of psoralen monoadduct and crosslink formation.", NUCLEIC ACIDS RESEARCH 22 (14). 1994. 2845-2852. ISSN: 0305-1048, XP002018568 *
HAVRE P A ET AL: "Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide.", JOURNAL OF VIROLOGY 67 (12). 1993. 7324-7331. ISSN: 0022-538X, XP002018570 *
HAVRE PA ET AL: "Targeted mutagenesis of DNA using triple helix-forming oligonucleotides linked to psoralen.", PROC NATL ACAD SCI U S A, AUG 15 1993, 90 (16) P7879-83, UNITED STATES, XP002018569 *
RAHA M ET AL: "Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant.", PROC NATL ACAD SCI U S A, APR 2 1996, 93 (7) P2941-6, UNITED STATES, XP002018566 *
WANG G ET AL: "Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation.", MOLECULAR AND CELLULAR BIOLOGY 15 (3). 1995. 1759-1768. ISSN: 0270-7306, XP002018567 *

Also Published As

Publication number Publication date
AU6043296A (en) 1996-12-24
WO1996039195A2 (fr) 1996-12-12

Similar Documents

Publication Publication Date Title
ATE161541T1 (de) Chemische-modifizierte oligonukleotide für site- spezifisches mutagenesis
WO1996039195A3 (fr) Oligonucleotide chimiquement modifie pour mutagenese dirigee sur site
WO1999064582A3 (fr) Criblage de fonction genique a haut rendement a l'aide de banques d'applications genomiques fonctionnelles
EP0348458A4 (en) Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
WO2001090337A3 (fr) Detection d'arn
ZA981762B (en) Nucleic acid molecules encoding enzymes having fructosyl polymerase activity.
DK0868530T3 (da) Kaskade-nucleinsyreamplificeringsreaktion
BG100188A (bg) Ензими за секвениране на днк
DE69433626D1 (de) N-2 substituierte purine
IL70765A0 (en) Methods and structures employing non-radioactive chemicallylabeled polynucleotides
EP0760002A4 (fr) Detection de mutations par clivage par resolvase
EP1504093A4 (fr) Enzymes de d tection de l'arn
WO1995023225A3 (fr) Procede et reactif inhibiteur de l'expression de genes concernant une affection
CA2205382A1 (fr) Molecules d'adn enzymatiques
ZA853756B (en) Nucleic acid hybridization assay employing immobilized rna probes
ATE202569T1 (de) Prodrug-oligonukleotide
DE69332666D1 (de) Verfahren zur einfachen nukleotid-primer-verlängerung zum nachweis spezifischer allele und dafür geeigneter kit
CA2124034A1 (fr) Gene codant pour une proteine regulatrice de la sensibilite a l'aureobasidine
ZA200101737B (en) Nucleic acid molecules which code for enzymes with fructosyltransferase activity and use thereof.
FR2735487B1 (fr) Procede de transformation catalytique d'hydrocarbures en composes aromatiques avec un catalyseur contenant des metaux alcalins ou alcalino-terreux
WO2002090300A3 (fr) Acides nucleiques et proteines presentant une activite de thioredoxine reductase
WO1994000572A3 (fr) Gene de l'ataxie-telangiectasies du groupe de complementation d (atdc)
EP0398709A3 (fr) Diagnostic génétique de dystonie de torsion
WO2002030266A3 (fr) Detection d'adn endommage
GB2197651B (en) Rna polymerase gene microorganism having said gene and the production of rna polymerase by the use of said microorganism

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR CA CN CZ EE FI GE HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BB BG BR CA CN CZ EE FI GE HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA